{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:18:02Z","timestamp":1788351482908,"version":"build-2803163510"},"reference-count":17,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,16]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Accumulating evidence from randomized phase 3 trials in multiple tumor types supports the application of neoadjuvant or perioperative immunotherapy to significantly enhance clinical benefit in patients with resectable solid tumors. While systemic immunotherapy in this setting can be very effective, immune-related toxicity and resistance remain important challenges. Local administration of immune checkpoint blockade and\/or other immune modulatory agents at lower doses offers a promising alternative strategy. Access to the proximal tumor microenvironment and tumor-draining lymph nodes (TDLNs) minimizes systemic exposure and potentially mitigates toxicity without compromising efficacy. Local neoadjuvant immunotherapy may enable more potent immune priming and activation within preserved TDLN, potentially reducing both local and distant recurrence rates and improving clinical outcomes. The availability of post-treatment resection specimens allows for the subsequent in-depth analysis of induced immune responses and co-evolving resistance mechanisms. Notwithstanding these potential advantages, challenges remain, such as lack of consensus on preferred delivery techniques, optimal (combinatorial) agents, dosing, and timing of administration. Carefully designed clinical trials, randomized against systemic administration, are needed to address these issues, establish durable clinical benefit, and guide broader implementation of locally administered neoadjuvant immunotherapy.<\/jats:p>","DOI":"10.1136\/jitc-2025-014324","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:30:28Z","timestamp":1778682628000},"page":"e014324","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03698019","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04949113","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03553836","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04099251","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01042379","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04185311","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06736379","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06095674","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3976-0694","authenticated-orcid":false,"given":"Marije A","family":"Strikwerda","sequence":"first","affiliation":[{"name":"Department of Gynecological Oncology, Amsterdam UMC Location VUmc, Amsterdam, Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Centre Amsterdam, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8431-7557","authenticated-orcid":false,"given":"Lotte L","family":"Hoeijmakers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Division of Immunology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie P G R","family":"Veenstra","sequence":"additional","affiliation":[{"name":"Cancer Biology and Immunology, Cancer Centre Amsterdam, Amsterdam, Netherlands"},{"name":"Department of Medical Oncology, Amsterdam UMC Location VUmc, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons J M","family":"Van Den Eertwegh","sequence":"additional","affiliation":[{"name":"Cancer Biology and Immunology, Cancer Centre Amsterdam, Amsterdam, Netherlands"},{"name":"Department of Medical Oncology, Amsterdam UMC Location VUmc, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7095-1771","authenticated-orcid":false,"given":"Mariette","family":"Labots","sequence":"additional","affiliation":[{"name":"Cancer Biology and Immunology, Cancer Centre Amsterdam, Amsterdam, Netherlands"},{"name":"Department of Medical Oncology, Amsterdam UMC Location VUmc, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U","family":"Blank","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Division of Immunology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands"},{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands"},{"name":"Division of Melanoma and Sarcoma, European Institute of Oncology, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-2031","authenticated-orcid":false,"given":"Constantijne H","family":"Mom","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Amsterdam UMC Location VUmc, Amsterdam, Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Centre Amsterdam, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja D","family":"De Gruijl","sequence":"additional","affiliation":[{"name":"Cancer Biology and Immunology, Cancer Centre Amsterdam, Amsterdam, Netherlands"},{"name":"Department of Medical Oncology, Amsterdam UMC Location VUmc, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026090204400850000_14.5.e014324.1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","article-title":"The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types","volume":"6","author":"Awada","year":"2025","journal-title":"Nat Cancer"},{"key":"2026090204400850000_14.5.e014324.2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41577-025-01222-w","article-title":"Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape","volume":"26","author":"Fallarino","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"2026090204400850000_14.5.e014324.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0781"},{"key":"2026090204400850000_14.5.e014324.4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay3575","article-title":"Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy","volume":"12","author":"Francis","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026090204400850000_14.5.e014324.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604"},{"key":"2026090204400850000_14.5.e014324.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"2026090204400850000_14.5.e014324.7","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-025-01118-9","article-title":"Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma","volume":"5","author":"Versluis","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"2026090204400850000_14.5.e014324.8","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaoncol.2023.2789","article-title":"Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial","volume":"9","author":"Dummer","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026090204400850000_14.5.e014324.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.10.007"},{"key":"2026090204400850000_14.5.e014324.10","doi-asserted-by":"crossref","first-page":"112914","DOI":"10.1016\/j.ejca.2023.05.003","article-title":"Adjuvant therapy for stage II melanoma: the need for further studies","volume":"189","author":"Lee","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026090204400850000_14.5.e014324.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02583-2"},{"key":"2026090204400850000_14.5.e014324.12","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"2026090204400850000_14.5.e014324.13","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn8097","article-title":"Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation","volume":"7","author":"van Pul","year":"2022","journal-title":"Sci Immunol"},{"key":"2026090204400850000_14.5.e014324.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.09.001"},{"key":"2026090204400850000_14.5.e014324.15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"key":"2026090204400850000_14.5.e014324.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0944"},{"key":"2026090204400850000_14.5.e014324.17","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.19.02985","article-title":"Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST","volume":"38","author":"Goldmacher","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:40:17Z","timestamp":1788349217000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014324"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014324","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}